With the advancement of bioinformatics in molecular modeling, we aimed to demonstrate the activity of GP63 and its anticancer peptides on melanoma using a range of in silico tools and screening methods to identify predicted and designed anticancer peptides. The gene discussed is LMLN; the disease is melanoma.